fifth about deliver and to consecutive and Plus constant constant the AdTab, our EPS quarter, was currency Thanks, we line to organic adjusted constant reported our of continue adjusted of X% Katy. products, X% quarter marks Elanco Good revenue currency ranges. and underlying currency from led midpoint in the new above driven XXXX. contribution organic top delivering Experior, of everyone. This business, growth strong third a with EBITDA our Credelio revenue Organic in by by morning, of growth expect growth guidance growth Zenrelia.
flow. strategy. Beginning focused milestones innovation, products growth, achieved we on off paying cash key strategy and enabling with Slide and advancing innovation on productivity driving consistent innovative new improved X, Our growth, our cash is portfolio
excluding by our U.S. of Third Aqua revenue pet impact divestiture growth, our quarter the farm international businesses. health and was led
overall, last year. we Elanco, milestones blockbuster we call, quarter organic achieved to our commercial for next now Since and into fourth products accelerate sequentially into earnings key shift For several in we expect launch as from regulatory growth mode. potential the
meaningful we health both the On in largest received differentiated Zenrelia FDA the markets X positively side, health. Quattro for pet be pet and competitors approval U.S. products expected Credelio in to
into house, On methane from beginning derived the emission of signed farm feeding dairy side, carbon credits is consumer good from to Bovaer the use the packaged to purchase on-farm move flywheel as contracts Bovaer Appian first multiple cows. from have saw the to in-set dairy reduce companies
the of in third we $X.X As enabled we Aqua of down the paid in billion debt divestiture August, quarter, our by business. shared
Debt and the year. end down start leverage paydown be the in to mid-Xx the our remains top of from net of year, mid-Xx capital expected the allocation at this the now range priority at
we expected new mid-single $XXX in organic our we're to XXXX. digits million with growth continued from million framework revenue introducing XXXX in our to Finally, today, accelerate expect expectations, currency $XXX around to products, a of confidence constant XXXX
Aqua launches. divestiture We health excluding the to adjusted underlying pet strategically new growth mid-single-digit in business expect EBITDA we drive the our as invest
digits X headwind of driven court the from organic by supervised U.K. expect solvency of an located to the and expected grow adjusted in our CMOs key we Ultimately, EBITDA single low
to the in end net low continue range. to of will address We be leverage remarks. our to X% further Xx Todd the year-end our outlook high expect towards prepared
currency business revenue Aqua growth constant underlying divestiture growth of areas. third the to by our out provide We separated X. the the show Slide to We've year-over-year X of organic Moving X%. quarter impact
revenue, clinic. Health pressure declined the Pet performance vet with quarter which vaccine in by was and offset in starting competitive volatility strong the the more supply X% U.S. retail than as First,
business On the sales continued over the all quarter. to as the the third trends U.S. we retail starting in in saw grew side, growth third quarter, XX% volume. dispensing returned Seresto the driven by in May positive
On the excited vet the in Quattro. the we're the and launch of side, Zenrelia Credelio XXXX expected launch third first quarter about quarter of
pet delivered revenue and to be of These products to into key X%, growth U.S., this driven year quarter XXXX. will Health in growth return Outside contributors of constant U.S. the currency business of less fourth volume Plus the year the of by expected as Seresto. and of has this and points expectations quarter existing strength in Credelio both continued AdTab our retail the fat to cannibalization analysis each source channels. our ADTab exceeded portfolio our Pet
brand driving in both new is over-the-counter growth to more cats, and the strategic investment fast-growing competitors. dogs into AdTab for oral than users category lead the Our market recruiting
continued key brand-building Across in survey investment. penetration positive markets reorder we in while Europe, and seeing channels consumer preference significant are very supports rates, data high
in key as driver ADTab expect a XXXX be well. to We growth
to globally. cattle. moving Now The by remains U.S. numbers, cattle business the in grew Elanco's led grew XX%, strong, animal X% U.S. cattle business by led farm decline revenue Despite Experior.
are population, we With broader Heifers in sales into XXXX. growth which of XX% expect status to Experior continued reach to expected blockbuster to a represents year. allow globally combination exceed driver feedlot for approvals U.S. for million key with clearance nearly strong now Recent expected this expansion the Experior $XXX performance,
for continues Additionally, last third X year, favorable the as than we vaccines see the from to to of Cattle continue very but benefited to the to our extent a deliver. quarter prior comparisons portfolio strength quarters. integrated strong lesser Rumensin in demand
impacting the investment and productivity reducing in economics products. in producer industry are the other certain difficult U.S. producers as are swine, In
in continue XXXX. to dynamic this expect We
the benefited again poultry Finally, our third portfolio quarter. from in rotations
in business in into expect variability purchasing patterns quarter in first the our in positive growth late driven half rotations XXXX. and by performance the this the fourth a Given and we of headwind to XXXX,
due recall. 'XX as the stabilizing commercial as changes farm to products, constant the a consecutive base, with we're initial growth the the and revenue factors: revenue the our international underlying currency from product us we fifth in by X% model X Overall, impact Kexxtone intentional Finally, different the performance by well with price driven the guidance introduced with quarter growth. was discrete along animal, allowing by business, organic encouraged decline of led of new report the
X. Slide to Moving
our a quarter, We innovation productivity the portfolio continue and to at was X% To is highlights, on price year-to-date strategy. of advance hit the third growth ratio leverage net the X.Xx our basis. end and
million of on as on $XXX million innovation the XXXX million now our and million shown which the are the to range million we million expected $XX sales $XXX quarter expectations full third to X. with $XXX year year-to-date of sales, Slide for bringing million and delivered for up year. tightening basis, to a Today, Now in $XXX the bottom XXXX end innovation, of $XXX $XXX next by on
of as Third Credelio U.S. launch quarter driven momentum growth September. and as late was by Plus Brazil well Experior, AdTab the in continued and Zenrelia from
talk innovation Now our X. products on key let's about detail X in more Slide
to well. thrilled company the our $X.X late animal market. the are enter second progressing dermatology launch Since billion health to U.S. is very global We be in September, the approval
on we now internal hitting all in pleased conference been September to call XX. out the as we've metrics laid key be are executing strategy our our We
buy. the Focusing incentive first driving and to education, experience accelerating on vet positive
data sales life label the in and strategy study U.S. starts the the Our to bring field product who considerations with vet clinic, head-to-head the results. product our and utilizing education team, benefits
several the hosted experiences. and weeks, Board-certified positive over meetings, regional and thought Additionally, their numerous have boards, dinner advisory shared where past well-respected weekly education we have veterinary medical meetings webinars dermatologists leaders
case studies and successful These clinical discussions from outcomes data include participants. trial
with Our and survey increases KOLs shows points significantly veterinarian buy touch peers. data intent these the educational to after
a days of or presented Symposium. following and the groups. the Additionally, with at vaccinations titers including rabies when X on ilunocitinib time XX booster all vaccine at Xx days mid-October, label in results study dose, similar XX booster that Zenrelia of XX treated was core concluded The for administered, were canine were among number administration dogs and dogs control the protected promising
No Elanco to veterinarians to interested questions our is regional on and and support The individual data veterinarians accessible were serious adverse decisions. treatment consulting events continue provide observed.
a experience. is our strategy of pillar second driving The positive
early continue and case around real-world variety to a targeted Zenrelia valuable types. We success of gain a enrolled execute to adopters We a program, different us in strategy. of outcomes data experience had number of our sample early allowing
used our launch profile and it and product reorder to the been clear order passed a Zenrelia types all weeks is few the dogs. for line treatment. presented, works, very rates be and that speed all improvements booster data has experienced works see We was size veterinarians clinic expectations. With with average only the pleased be metrics, of their have are and very to vaccine in of with a in It well. Zenrelia progressing including the allergic level opportunity Both owners pet it the first-line itch believe cases have clear a since penetration, and key of really
for clinics, clinic reorder many demonstrating tracking tracking being indicator product We is are the key used The are and replenished. penetration. we leading rates is
the the year. on next update week. beginning market seeing quarterly metric are hundreds to in product new We plan of clinics We placed early each this
motion, continue Zenrelia pleased Overall, launch execute we a Brazil. approach. launch with seeing global Our invest are in the we the no-regrets are and is both and in and adoption by of we the encouraged full U.S. to and in
over restrictive Japan fastest for globalization We and look Canada to of with and both a launching labels the the coming the months. less launch ever U.S. than with forward Elanco approved, now
are benefits in company to We in the thrilled and be dermatology the offer. strongly second treatment canine space to offer Zenrelia has believe new innovative just to an efficacy
dermatitis has lever grow to We potential while Zenrelia cases see and significant and the relevance a product Elanco. of all the for atopic for for believe market this growth unleashing
on the focused position beginning. just sustainable dermatology in is and are leadership We building Zenrelia a
the to Cat less includes Credelio Credelio approval Plus. newest Credelio Quattro, Dog, Credelio Zenrelia, month and expected, the for the received Credelio Additionally, than as approval after addition we FDA a franchise, U.S. of which
species fleas, the canine hookworms, Credelio monthly parasiticide to roundworms, of tick, protect heart against and oral and different worms, in Quattro dose. is single X a first tapeworm only
the this differentiated U.S. nearly to $X.X tick of broad are in We market intestinal XX% thrilled up market. insecticides spectrum making with products now flea, parasiticides parasite these the product and billion market. combination fastest-growing are category or U.S. to the bring products the
And prescription Quattro proposition the parasiticide value is in to market. positioned also Elanco's strengthen
XXXX, season. final first progressing the scale-up through of of prior remains for stages which track to on major launch, the quarter the optimize are parasiticide manufacturing the nicely We to
We expect growth to for be market of consumer-focused Quattro share launch, Credelio the the a overall growth driving parasiticide Elanco. to contributing major
sale first progress and farm cows several dairy use we were innovation, state production the the California, by Bovaer, to are achieved we animal Notably, for permission and key of and Bovaer. a the fed Shifting milestones. encouraged granted was of in also Bovaer key
by cows of year. the end the enrolled with expected XXX,XXX uplook our robust. expand very trend reach X to activated database approximately cows is and demand continue million the to farmer of We Overall towards dairy
And credits. finally, contracts CPG these can companies you entering as on commercial in-set Slide now carbon purchase chart the majority products. the or are We've for multiple updated And see, execution large in we pipeline signed have in phase to of X. our
these share of but coming indicators to progress information more launches the excited in are the positive. We on are quarters, early
focused build on ramp strong are over discuss share, that, brands. With quarter adoption, to third and to appropriately markets investing and We more detail. our it expand outlook take in Todd hand results to I'll
